- Home
- QCRH vs DVAX Comparison
QCRH vs DVAX Comparison
Compare QCRH & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- DVAX
- Stock Information
- Founded
- QCRH 1993
- DVAX 1996
- Country
- QCRH United States
- DVAX United States
- Employees
- QCRH N/A
- DVAX N/A
- Industry
- QCRH Major Banks
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- DVAX Health Care
- Exchange
- QCRH Nasdaq
- DVAX Nasdaq
- Market Cap
- QCRH 1.2B
- DVAX 1.3B
- IPO Year
- QCRH 1993
- DVAX 2004
- Fundamental
- Price
- QCRH $78.96
- DVAX $10.50
- Analyst Decision
- QCRH Buy
- DVAX Buy
- Analyst Count
- QCRH 3
- DVAX 4
- Target Price
- QCRH $88.83
- DVAX $26.50
- AVG Volume (30 Days)
- QCRH 99.6K
- DVAX 1.5M
- Earning Date
- QCRH 07-23-2025
- DVAX 08-07-2025
- Dividend Yield
- QCRH 0.31%
- DVAX N/A
- EPS Growth
- QCRH N/A
- DVAX N/A
- EPS
- QCRH 6.63
- DVAX N/A
- Revenue
- QCRH $322,873,000.00
- DVAX $316,268,000.00
- Revenue This Year
- QCRH N/A
- DVAX $23.23
- Revenue Next Year
- QCRH $7.11
- DVAX $16.57
- P/E Ratio
- QCRH $11.85
- DVAX N/A
- Revenue Growth
- QCRH N/A
- DVAX 26.66
- 52 Week Low
- QCRH $60.83
- DVAX $9.22
- 52 Week High
- QCRH $96.08
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- QCRH 70.85
- DVAX 45.80
- Support Level
- QCRH $74.50
- DVAX $10.28
- Resistance Level
- QCRH $76.17
- DVAX $11.45
- Average True Range (ATR)
- QCRH 1.52
- DVAX 0.46
- MACD
- QCRH 0.44
- DVAX -0.05
- Stochastic Oscillator
- QCRH 98.81
- DVAX 29.09
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.